Last reviewed · How we verify
NCT05742724: POT-GFR-PK
The Pharmacokinetics of Single Dose Oral Tetrahydrocannabinol and Cannabidiol
Phase 1 trial testing Tetrahydrocannabinol-Cannabidiol Combination in Cannabis in 24 participants. Participants enrolled and being followed up; not accepting new ones.
16 February 2024
Quick facts
| Lead sponsor | McMaster University |
|---|---|
| Phase | Phase 1 |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | other |
| Enrollment | 24 |
| Start date | 11 January 2024 |
| Primary completion | 16 February 2024 |
| Estimated completion | 1 March 2025 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- Tetrahydrocannabinol-Cannabidiol Combination — full drug profile →
Conditions studied
- Cannabis — all drugs for Cannabis →
- Chronic Kidney Diseases — all drugs for Chronic Kidney Diseases →
- Dialysis — all drugs for Dialysis →
Sponsor
McMaster University
Who can join
25 and older, any sex, with Cannabis or Chronic Kidney Diseases. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
POT-GFR-PK is a single dose pharmacokinetic study oral tetrahydrocannabinol (THC) and cannabidiol (CBD) in healthy adult controls and individuals with chronic kidney disease including those treated with in-center hemodialysis.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05742724
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cannabis
Currently open trials in the same condition.
- NCT05999383 — Understanding the Clinical Pharmacology of Marijuana-Tobacco Co-administration · Phase 2 · recruiting
- NCT07417059 — Sex Hormones Impact on Cannabis Response · NA · recruiting
- NCT07194018 — Use of Cannabis Oil in Fibromyalgia · active not recruiting
- NCT06099379 — Modulation of THC Effects by CBD: a Dose-ranging Study · Phase 1, PHASE2 · recruiting
- NCT05514899 — Effects of Cannabidiol and Tetrahydrocannabinol on Microbiome and Neuroinflammation in HIV · Phase 2 · recruiting
Other McMaster University trials
Trials by the same sponsor.
- NCT06231069 — Mixed Exercise Training and Novel Multi-Nutrient Supplementation in Young Adults · NA · withdrawn
- NCT07213492 — Multimodal Intervention to Support Hospital-to-Community Transition in Bipolar Disorder · NA · recruiting
- NCT07486505 — Mindfulness in Fracture Recovery and Reduction of Opioid Reliance: Evaluating the Feasibility of Implementing a Brief, M · NA · not yet recruiting
- NCT07408128 — Partner4Exercise Randomized Controlled Trial · Phase 2, PHASE3 · not yet recruiting
- NCT07459777 — Early arthroscoPic Stabilization veRsus rehabilitatiOn of the Shoulder in Adolescents With a trauMatic First-time Anteri · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05742724 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by McMaster University
- Last refreshed: 20 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05742724.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing